Myomo adds William Febbo to board of directors

Rhea-AI Filing Summary

Myomo, Inc. appointed William “Will” Febbo to its Board of Directors effective April 14, 2026, as a Class II director serving until the 2028 annual meeting, bringing over 30 years of experience in healthcare, financial services, and technology-driven businesses.

As a non-employee director, he was granted 45,000 restricted stock units (RSUs) that vest on the first anniversary of his appointment. He will also receive an annual cash retainer of $60,000 and an additional $85,000 per year in RSUs vesting quarterly. The company highlighted his prior leadership at OptimizeRx, where revenue expanded from $5 million to $92 million with a five-year CAGR of 41%, and his capital markets background as important additions to Myomo’s board.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Initial RSU grant: 45,000 RSUs Annual cash retainer: $60,000 Annual RSU retainer: $85,000 in RSUs +4 more

7 metrics

Initial RSU grant 45,000 RSUs Granted to William Febbo upon board appointment, vesting after one year

Annual cash retainer $60,000 Yearly cash compensation for William Febbo as a non-employee director

Annual RSU retainer $85,000 in RSUs Equity portion of director compensation, vesting over four quarters

OptimizeRx revenue growth $5M to $92M Revenue increase at OptimizeRx during William Febbo’s tenure as CEO

OptimizeRx CAGR 41% five-year CAGR Compound annual growth rate in revenue under Febbo’s leadership

Board size after appointment 6 directors Total number of Myomo directors following William Febbo’s addition

Industry experience 30+ years William Febbo’s experience across healthcare, financial services, technology

Key Terms

restricted stock units, Regulation FD Disclosure, emerging growth company, indemnification agreement, +2 more

6 terms

restricted stock units financial

"Mr. Febbo was granted 45,000 restricted stock units ("RSUs"), which will vest..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On April 16, 2026, the Company issued a press release..."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers..."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

indemnification agreement regulatory

"Mr. Febbo has entered into an indemnification agreement with the Company..."

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

capital markets initiatives financial

"guided organizations through substantial growth, strategic transformations and acquisitions, and significant capital markets initiatives."

compound annual growth rate financial

"revenue grew from $5 million to $92 million, achieving a five-year CAGR of 41%."

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Myomo (MYO) announce in this 8-K filing?

Myomo announced the appointment of William “Will” Febbo to its Board of Directors as a Class II director, effective April 14, 2026. He will serve until the 2028 annual meeting, expanding the board to six directors and adding significant healthcare and capital markets experience.

Who is William Febbo and what experience does he bring to Myomo (MYO)?

William “Will” Febbo is an executive with over 30 years of experience in healthcare, financial services, and technology. He previously led OptimizeRx as CEO, growing revenue from $5 million to $92 million and overseeing its evolution into an AI-driven omnichannel digital healthcare platform.

What compensation will William Febbo receive as a Myomo (MYO) director?

Upon joining the board, William Febbo received 45,000 restricted stock units vesting after one year. As a non-employee director, he will also receive a $60,000 annual cash retainer and $85,000 per year in RSUs that vest over four quarterly installments.

How did OptimizeRx grow under William Febbo’s leadership cited by Myomo (MYO)?

Myomo notes that under William Febbo’s leadership, OptimizeRx’s revenue increased from $5 million to $92 million, achieving a five-year compound annual growth rate of 41%. He also led its uplisting to Nasdaq and expansion of its digital healthcare network and market capitalization.

Does William Febbo have any related-party transactions with Myomo (MYO)?

The filing states that William Febbo is not a party to any transaction with Myomo requiring disclosure under Item 404(a) of Regulation S-K. It also notes there are no arrangements or understandings with other persons pursuant to which he was selected as a director.

How many directors does Myomo (MYO) have after appointing William Febbo?

Following William Febbo’s appointment, Myomo’s board consists of six directors. The company emphasizes his expertise in direct-to-patient healthcare solutions and capital markets as complementary skills to the existing board as it executes its strategy for 2026 and beyond.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:18 PM Learn about SEC filing dates

false00013692900001369290dei:FormerAddressMember2026-04-142026-04-1400013692902026-04-142026-04-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2026

MYOMO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38109	47-0944526
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
45 Blue Sky Dr. Suite 101
Burlington, Massachusetts				01803
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 996-9058

,

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		MYO		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 14, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Myomo, Inc. (the "Company"), the Board appointed William J. Febbo to join the Board, effective on April 14, 2026. Mr. Febbo will serve as a Class II director until his term expires at the 2028 annual meeting of shareholders, at which time he will stand for election by the Company’s shareholders. Mr Febbo has not been appointed to serve on any committees of the Board.

Mr. Febbo, 57, currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately-held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024. Mr. Febbo has also co-founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo holds a BA in International Studies and Spanish from Dickinson College. He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges. He also serves as a Mentor for the X & Y Class at Harvard Business School.

In connection with his appointment to the Board, Mr. Febbo was granted 45,000 restricted stock units ("RSUs"), which will vest in their entirety on the first anniversary of the effective date of his appointment to the Board. As a non-employee director, Mr. Febbo will also receive an annual cash retainer of $60,000. In addition, Mr. Febbo will be entitled to receive $85,000 annually, paid in the form of RSUs, which vest over four quarters .Mr. Febbo is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Febbo and any other persons pursuant to which he was selected as a director. In addition, Mr. Febbo has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

Item 7.01 Regulation FD Disclosure.

On April 16, 2026, the Company issued a press release announcing the appointment of Mr. Febbo. A copy of the Company’s press release relating to this announcement is attached as Exhibit 99.1 to this current report on Form 8-K (the “Report”).

The information contained in Item 7.01 of this Report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Myomo, Inc. on April 16, 2026. furnished herewith.
104		The cover page from the Company’s Form 8-K dated April 16, 2026, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Myomo, Inc.
Date:	April 16, 2026	By:	/s/ David A. Henry
			David A. Henry Chief Financial Officer

Exhibit 99.1

Myomo Appoints William J Febbo to its Board of Directors

BURLINGTON, MA. (April 16, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William “Will” Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors.

Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant capital markets initiatives.

“We are pleased to welcome Will to our Board of Directors,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. "I’m looking forward to Will’s contributions, particularly his expertise in scaling innovative direct-to-patient healthcare solutions which is a key piece of strategy for 2026 and beyond. Additionally, his experience and credibility within capital markets should increase overall awareness of Myomo’s story as a solid investment thesis. "

Mr. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately-held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point-of-care product provider into an AI-driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five-year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co-founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network.

“My interest in Myomo stems from seeing the world adopting robotics within healthcare and looking for platforms which can scale and enable mobility for individuals in need. Myomo is poised to become a market leader in the field of advanced upper extremity orthotics,” said Mr. Febbo. “I look forward to supporting the Company’s continued innovative product development and commercial growth. Focusing on building a platform to unlock additional value as it scales access to its technology for patients with upper extremity weakness or paralysis.”

Mr. Febbo holds a BA in International Studies and Spanish from Dickinson College. He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges. He also serves as a Mentor for the X & Y Class at Harvard Business School.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com

clinical professionals across the U.S. and representatives internationally.

For more information, please visit www.myomo.com.

Contacts:

Myomo

ir@myomo.com

Alliance Advisors IR

Tirth T. Patel

tpatel@allianceadvisors.com

212-201-6614

# # #

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 17.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 41.8 KB